CHICAGO — Patients with advanced melanoma treated with a PD-1 immune checkpoint inhibitor lived more than twice as long as historically treated patients, according to updated results from a large phase I clinical trial.
Conferences
Targeted Checkpoint Blocking Therapies Not Yet an Effective Melanoma Treatment, Cancer Expert Says
In a talk at the recent HemOnc Today’s Melanoma and Cutaneous Malignancies meeting, Christian Blank, group leader of the division of immunology at Netherlands Cancer Institute, presented his views of checkpoint blocking therapies. He concluded that targeted therapy is not enough to fight melanoma.
VIDEO: Targeted therapy ‘not enough’ for long-term melanoma treatment
Christian Blank, MD, PhD, staff member in medical oncology and group leader of the division of immunology at Netherlands Cancer Institute, reviewed new checkpoint targets during a presentation at HemOnc Today Melanoma and Cutaneous Malignancies.
VIDEO: Rational strategy necessary for clinical follow-up in melanoma
NEW YORK — Merrick I. Ross, MD, professor in the department of surgery at The University of Texas MD Anderson Cancer Center, offered recommendations for clinical follow-up of patients with melanoma during a presentation at HemOnc Today Melanoma and Cutaneous Malignancies.